Antimicrob Agents Chemother. 2016 May 9. pii: AAC.00627-16. [Epub ahead of print]

In vitro activity of lefamulin tested against Streptococcus pneumoniae with defined serotypes, including multidrug-resistant isolates causing lower respiratory tract infections in the United States.

Mendes RE1, Farrell DJ2, Flamm RK2, Talbot GH3, Ivezic-Schoenfeld Z4, Paukner S4, Sader HS2.

Author information


Lefamulin was evaluated against various S. pneumoniae serotypes collected from adults with lower respiratory tract infections. Lefamulin exhibited MIC50/90 of 0.12 and 0.25 μg/ml, respectively, against the entire collection (n=822). Similar results were obtained for lefamulin against each of most common serotypes, as well as multi-drug resistant isolates and strains non-susceptible to ceftriaxone or erythromycin. These data support the clinical development of lefamulin for the treatment of community-acquired respiratory tract infections.

Copyright © 2016, American Society for Microbiology. All Rights Reserved.

PMID: 27161634 [PubMed - as supplied by publisher]